ERF Stock Analysis: Eurofins Scientific SE | PA
Diagnostics & Research | PA, France | Market Cap: 13.094m EUR | 12M Return: 24.1% | FR0014000MR3 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 27.6M
EPS Trend: -10.6%
Rev. Trend: 80.5%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Eurofins Scientific SE is a Luxembourg-headquartered company founded in 1987 that operates as a global provider of analytical testing and laboratory services. Its business model centers on delivering outsourced, contract-based laboratory testing and certification to clients across multiple industries rather than manufacturing or selling products of its own.
The company offers testing and consultancy services across a broad portfolio, spanning agroscience (including biological assessment, regulatory consultancy, and seed services), agro testing, assurance and certification, biopharma, and clinical diagnostics. It also serves consumer products, cosmetics and personal care, electrical and electronics, and environmental testing categories (covering water, air, soil, waste, microplastics, and radioactivity). Food and feed testing is another major line, addressing allergens, microbiology, GMO, mycotoxins, pesticides, and nutritional analysis, among others.
Additional service areas include forensic, maritime, materials and engineering, REACH compliance, genomic and sensory/consumer services, in vitro diagnostics, and PSS insourcing solutions. Classified under the Health Care sector and Biotechnology sub-industry in the GICS classification, Eurofins combines healthcare-related diagnostics and biopharma testing with industrial and environmental analytical work, giving it a diversified revenue base across regulated end markets.
- Agro testing and food safety demand drives organic revenue growth
- Biopharma services margin expansion on clinical diagnostics scaling
- Regulatory testing tailwinds from REACH and environmental compliance mandates
- European lab consolidation strategy accelerates bolt-on M&A and capital deployment
| Net Income: 530.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.20 > 1.0 |
| NWC/Revenue: 4.43% < 20% (prev 7.47%; Δ -3.04% < -1%) |
| CFO/TA 0.12 > 3% & CFO 1.36b > Net Income 530.4m |
| Net Debt (5.29b) to EBITDA (1.49b): 3.55 < 3 |
| Current Ratio: 1.13 > 1.5 & < 3 |
| Outstanding Shares: last quarter (183.7m) vs 12m ago -5.89% < -2% |
| Gross Margin: 11.97% > 18% (prev 22.59%; Δ -10.62% > 0.5%) |
| Asset Turnover: 68.08% > 50% (prev 67.49%; Δ 0.59% > 0%) |
| Interest Coverage Ratio: 4.98 > 6 (EBIT TTM 918.7m / Interest Expense TTM 184.4m) |
| A: 0.03 (Total Current Assets 2.81b - Total Current Liabilities 2.49b) / Total Assets 11.1b |
| B: 0.29 (Retained Earnings 3.17b / Total Assets 11.1b) |
| C: 0.08 (EBIT TTM 918.7m / Avg Total Assets 10.8b) |
| D: 0.49 (Book Value of Equity 3.62b / Total Liabilities 7.46b) |
| Altman-Z'' = 2.20 = BBB |
| DSRI: 1.08 (Receivables 1.55b/1.40b, Revenue 7.38b/7.14b) |
| GMI: 1.89 (GM 22.59% / 11.97%) |
| AQI: 0.96 (AQ_t 0.50 / AQ_t-1 0.52) |
| SGI: 1.03 (Revenue 7.38b / 7.14b) |
| TATA: -0.08 (NI 530.4m - CFO 1.36b) / TA 11.1b) |
| Beneish M = -2.17 (Cap -4..+1) = BB |
As of October 10, 2026, the stock is trading at EUR 77.12 with a total of 197,695 shares traded. Over the past week, the price has changed by +3.02%, over one month by +8.71%, over three months by +12.09% and over the past year by +24.06%.
Current recommended Stop Loss: 72.60 (which is 5.9% or 2.4 ATR below the current price).
Eurofins Scientific SE has no consensus analysts rating.
P/E Trailing = 26.5694
P/E Forward = 15.4083
P/S = 1.7729
P/B = 2.8206
P/EG = 0.9168
Revenue TTM = 7.38b EUR
EBIT TTM = 918.7m EUR
EBITDA TTM = 1.49b EUR
Long Term Debt = 3.41b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 772.0m EUR (from shortTermDebt, last quarter)
Debt = 5.91b EUR (from shortLongTermDebtTotal, last quarter) + Leases 435.9m
Net Debt = 5.29b EUR (calculated: Debt 5.91b - CCE 618.0m)
Enterprise Value = 18.4b EUR (13.1b + Debt 5.91b - CCE 618.0m)
Interest Coverage Ratio = 4.98 (Ebit TTM 918.7m / Interest Expense TTM 184.4m)
EV/FCF = 28.95x (Enterprise Value 18.4b / FCF TTM 634.9m)
FCF Yield = 3.45% (FCF TTM 634.9m / Enterprise Value 18.4b)
FCF Margin = 8.60% (FCF TTM 634.9m / Revenue TTM 7.38b)
Net Margin = 7.18% (Net Income TTM 530.4m / Revenue TTM 7.38b)
Gross Margin = 11.97% ((Revenue TTM 7.38b - Cost of Revenue TTM 6.50b) / Revenue TTM)
Gross Margin QoQ = 13.48% (prev 10.45%)
Tobins Q-Ratio = 1.65 (Enterprise Value 18.4b / Total Assets 11.1b)
Interest Expense / Debt = 3.12% (Interest Expense 184.4m / Debt 5.91b)
Taxrate = 27.44% (199.4m / 726.8m)
NOPAT = 666.7m (EBIT 918.7m * (1 - 27.44%))
Current Ratio = 1.13 (Total Current Assets 2.81b / Total Current Liabilities 2.49b)
Debt / Equity = 1.63 (Debt 5.91b / totalStockholderEquity, last quarter 3.62b)
Debt / EBITDA = 3.55 (Net Debt 5.29b / EBITDA 1.49b)
Debt / FCF = 8.33 (Net Debt 5.29b / FCF TTM 634.9m)
Total Stockholder Equity = 4.28b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.89% (Net Income 530.4m / Total Assets 11.1b)
RoE = 12.38% (Net Income TTM 530.4m / Total Stockholder Equity 4.28b)
RoCE = 11.94% (EBIT 918.7m / Capital Employed (Equity 4.28b + L.T.Debt 3.41b))
RoIC = 7.39% (NOPAT 666.7m / Invested Capital 9.02b)
WACC = 5.12% (E(13.1b)/V(19.0b) * Re(6.41%) + D(5.91b)/V(19.0b) * Rd(3.12%) * (1-Tc(0.27)))
Discount Rate = 6.41% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -93.24 | Cagr: -3.32%
[DCF] Terminal Value 75.63% ; FCFF base≈631.3m ; Y1≈641.4m ; Y5≈695.7m
[DCF] Fair Price = 32.16 (EV 10.8b - Net Debt 5.29b = Equity 5.50b / Shares 171.1m; r=8.35% [WACC [floored]]; 5y FCF grow 1.42% → 2.50% )
EPS Correlation: -10.59 | EPS CAGR: -1.50% | SUE: N/A | # QB: 0
Revenue Correlation: 80.55 | Revenue CAGR: 14.34% | SUE: 1.18 | # QB: 1
EPS current Quarter (2026-03-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=4.11 | Chg30d=-0.94% | Revisions=+0% | GrowthEPS=+5.6% | GrowthRev=+3.3%
EPS next Year (2027-12-31): EPS=4.64 | Chg30d=-1.18% | Revisions=+0% | GrowthEPS=+13.1% | GrowthRev=+5.4%
[Analyst] Revisions Ratio: +0% (up=2, down=2)